Related Experiment Video

Updated: Aug 23, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Dual infection in chronic hepatitis C patients

Eser Vardareli1, Tülay Sariçam, Aysegül Ozakyol

  • 1Osmangazi University Medical Faculty, Department of Gastroenterology, Eskisehir, Turkey.

Hepato-Gastroenterology
|July 13, 2004
PubMed

Insights

Previous or current Hepatitis B virus (HBV) infection is common in chronic Hepatitis C virus (HCV) patients. However, HBV coinfection does not significantly impact the clinical course or response to antiviral therapy in these patients.

Area of Science:

  • Hepatology
  • Virology
  • Gastroenterology

Background:

  • Hepatitis C virus (HCV) and Hepatitis B virus (HBV) coinfections can occur and persist in the same patient.
  • Previous studies have yielded varied results regarding the clinical impact of dual HCV/HBV infections.

Purpose of the Study:

  • To investigate the influence of prior or current HBV infection on the clinical progression and antiviral treatment outcomes in patients with chronic HCV infection.

Main Methods:

  • Retrospective analysis of 130 chronic hepatitis C patients, divided into two groups: Group 1 (n=50) with evidence of HBV exposure, and Group 2 (n=80) with HCV infection only.
  • Group 1 included patients with positive HBs Ag (n=12) or HBV antibodies (n=38).

Main Results:

  • No statistically significant differences were observed between groups in age, sex, follow-up duration, liver enzymes, liver function, histology, or Child-Pugh stage.
  • Hepatocellular carcinoma (HCC) incidence was similar between groups (2 in Group 1 vs. 6 in Group 2).
  • Antiviral therapy response and duration did not differ significantly between patients with and without HBV exposure.

Conclusions:

  • Previous or current HBV infection is frequently detected in patients with chronic HCV.
  • HBV coinfection does not appear to significantly alter the clinical course or response to antiviral therapy in chronic hepatitis C patients.
Abstract

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...